Related Experiment Videos
Phase I trial of pentamethylmelamine
Cancer Treatment Reports
|May 1, 1982
Summary
Pentamethylmelamine, an analog of hexamethylmelamine, showed antineoplastic activity but caused severe gastrointestinal and CNS toxicity in a phase I trial. Further trials are not recommended due to these dose-limiting side effects.
Area of Science:
- Oncology
- Pharmacology
- Clinical Trials
Background:
- Hexamethylmelamine is an established chemotherapy agent.
- Pentamethylmelamine was developed as an intravenous analog for improved administration.
- Phase I trials are crucial for evaluating the safety and tolerability of new cancer drugs.
Purpose of the Study:
- To assess the safety and tolerability of pentamethylmelamine in cancer patients.
- To determine the dose-limiting toxicities of pentamethylmelamine.
- To evaluate preliminary antineoplastic activity of pentamethylmelamine.
Main Methods:
- A phase I clinical trial was conducted involving 42 patients.
- Pentamethylmelamine was administered intravenously at doses ranging from 0.080 to 2.50 g/m2/day for 5 days.
- Treatment cycles were repeated approximately every 3 weeks.
Main Results:
- Dose-limiting toxic effects included moderate to severe nausea, vomiting, and central nervous system (CNS) toxicity.
- Myelosuppression was observed but was mild and not dose-limiting.
- Antineoplastic activity was noted in four patients, indicating potential efficacy.
Conclusions:
- Pentamethylmelamine demonstrated antineoplastic activity but was associated with unacceptable gastrointestinal and CNS toxicity.
- The observed toxic effects at active dose levels preclude recommendation for disease-specific phase II trials.
- Further development of pentamethylmelamine may require strategies to mitigate its significant side effects.